

(12) STANDARD PATENT APPLICATION (11) Application No. AU 2026201397 A1
(19) AUSTRALIAN PATENT OFFICE

(54) Title
A COMPOSITION, SYSTEM AND METHOD FOR REMOVAL OF DETERGENTS FROM AQUEOUS SOLUTIONS

(51) International Patent Classification(s)
C12N 15/10 (2006.01) **G01N 1/34** (2006.01)
B01D 17/00 (2006.01) **C02F 1/26** (2023.01)
C12Q 1/68 (2018.01) **C02F 1/58** (2023.01)

(21) Application No: **2026201397** (22) Date of Filing: **2026.02.25**

(43) Publication Date: **2026.03.19**

(43) Publication Journal Date: **2026.03.19**

(62) Divisional of:
2023237224

(71) Applicant(s)
DNA Genotek Inc.

(72) Inventor(s)
Birnboim, Hyman Chaim;Nepal, Rajeev Mani;Ray, Bitapi;Gage, Jessica Lynne;Askew, Christopher Gordon

(74) Agent / Attorney
James & Wells Intellectual Property, GPO Box 1301, CANBERRA, ACT, 2601, AU

ABSTRACT

The present application provides a system, composition, method and kit for removing a detergent, such as an anionic detergent, from an aqueous solution, comprising a salt, a water immiscible alcohol of Formula I:



where R^1 is an optionally substituted, linear, branched or cyclic $C_4 - C_{12}$ alkyl; and a water immiscible halocarbon, wherein said halocarbon is miscible with said alcohol of Formula I. The system can be used on aqueous solutions that contain detergents (such as Sodium Dodecyl Sulphate (SDS), for example), and any detergent-associated or detergent-bound molecules that may be present in the aqueous solution, to form an aqueous phase and a non-aqueous phase, for effectively removing the detergent and any detergent-associated or detergent-bound molecules, and sequestering them into the non-aqueous phase. The present composition, system, method and kit may, thus, ideally be used to remove inhibitors from aqueous solutions, i.e., inhibitors that inhibit reactions such as downstream applications including, but not limited to, Polymerase Chain Reaction (PCR, including Reverse Transcriptase-PCR (RT-PCR)), library preparation, and nucleotide sequencing. The aqueous phase may then be used directly for these downstream applications.

A COMPOSITION, SYSTEM AND METHOD FOR REMOVAL OF DETERGENTS FROM AQUEOUS SOLUTIONS

This application is a divisional application of AU 2023237224 the entire contents of which are incorporated herein by reference.

CROSS-REFERENCE TO RELATED APPLICATION

[0001] The present application claims priority from US Patent Application Serial No. 62/343,293, filed May 31, 2016, the entirety of which is herein incorporated by reference.

FIELD OF THE INVENTION

[0002] The present application pertains to a composition, system, method and kit for removing a detergent from an aqueous solution. The composition, system, method and kit of the present application may also be used for removing detergent-associated and/or detergent-bound molecules from aqueous solutions.

BACKGROUND

[0003] Sodium Dodecyl Sulphate (SDS) is an anionic detergent used in many cleaning and personal hygiene products. It is also commonly used in molecular biology applications such as SDS-PAGE (SDS-polyacrylamide gel electrophoresis) for studying proteins, in nucleic acid purification procedures, as well as in nucleic acid stabilization compositions.

[0004] When working with biological samples from which the release of nucleic acids is sought, the ability to dissolve cellular and particle membranes due to its amphipathic property is exploited in lysis buffers. Additionally, SDS binds tightly to proteins and is used to disrupt protein-nucleic acid interactions during extraction procedures. For example, SDS disrupts ionic interactions between positively-charged histones and the negatively-charged phosphates in the backbone of nucleic acids, thus helping to separate nucleic acids from proteins. Many common laboratory protocols for purifying deoxyribonucleic acid (DNA) make use of SDS, for example, conventional ethanol precipitation of DNA (Sambrook, Molecular Cloning: A Laboratory Manual (Third Edition)), lithium chloride precipitation (Sambrook, Molecular

Cloning: A Laboratory Manual (Third Edition)) or the SDS-alkaline denaturation method for obtaining plasmid DNA (Birnboim, H.C. (1983) *A Rapid Alkaline Extraction Method for the Isolation of Plasmid DNA.*, Methods Enzymol. 100, 243-55).

[0005] The ability of SDS to denature proteins by binding tightly to them and disrupting their structure results in the inactivation of most enzymes, including nucleases. This property is exploited for purposes of stabilizing and preserving nucleic acids in biological samples, as taught by Birnboim et al. in US7482116, US2010099149 and US2009123976. However, this property has the undesired effect of inhibiting enzyme-dependent reactions in subsequent applications using the nucleic acids if SDS is not thoroughly removed.

[0006] The abilities and characteristics of SDS are well known to those who practice the art of biochemistry and molecular biology. Most procedures to extract and purify nucleic acids do so by removing the nucleic acids from solution, leaving behind inhibitors and impurities. For example, addition of 1 to 2 volumes of ethanol to an aqueous solution causes the nucleic acids to precipitate, where they can be recovered from the pellet after a centrifugation step. Alternatively, nucleic acids can be bound to solid matrices, e.g., silica particles, from which they can be subsequently eluted. The resultant purified nucleic acid can be used in downstream applications such as the polymerase chain reaction (PCR), reverse transcriptase-PCR (RT-PCR), sequencing library preparation or sequencing.

[0007] There have been numerous attempts over the past 5 or 6 decades to simplify and improve procedures for the extraction and purification of nucleic acids. Typically, the reagents used in these procedures are inhibitory to downstream applications that utilize the purified nucleic acids. Therefore, reagents added to the initial sample during processing must be completely removed. For example, low concentrations of SDS are inhibitory to the Taq DNA polymerase used in PCR reactions. As little as 0.01% weight per volume of SDS in the final PCR is inhibitory, as reported by Weyant et al. 1990; Rossen et al. 1992; Saunders et al. 1999. This has been confirmed below. Several products exist in the market to remove SDS from samples (e.g., SDS Away™ [ProteaBiosciences]; Detergent-Out™ [Millipore]; SDS-Out™ [Pierce Biotechnology Inc.] are three examples), but these are optimized and formulated to remove SDS that is tightly bound to proteins rather than SDS present in solutions of nucleic acids.

2026201397 25 Feb 2026

[0008] At present there are 3 main classes of commercially available nucleic acid purification kits: (i) phenol-based extraction methods (e.g., Trizol™ [Invitrogen] and TriReagent™ [Molecular Research Centre, Inc.]), (ii) guanidinium-based binding of nucleic acids to solid matrices (e.g., silica surfaces on magnetic beads and columns) and (iii) SDS-based methods. Some SDS-based chemistries are incompatible with guanidinium-based chemistries because mixing the two reagents results in the precipitation of SDS as the insoluble guanidinium salt. The presence of SDS during a phenol/chloroform extraction has been observed to cause a milky precipitate to form. However, it has been observed that an SDS-containing sample could be processed in phenol/chloroform-based or guanidinium-based chemistries, provided the SDS was substantially removed beforehand. A simple way to lower the SDS concentration would be to dilute the sample to a level where SDS no longer precipitates, but that would introduce a need to concentrate the sample at a later step. Simple and rapid removal of SDS from an aqueous sample is an unmet need in the biochemistry and molecular biology arts.


[0009] Therefore, there remains a need for a composition and method that, when used on any aqueous solution that contains an anionic detergent, can effectively remove the detergent to barely detectable levels (less than 0.01% wt/vol) in an easy, rapid and efficient manner.

[0010] This background information is provided for the purpose of making known information believed by the applicant to be of possible relevance to the present invention. No admission is necessarily intended, nor should be construed, that any of the preceding information constitutes prior art against the present invention.

SUMMARY OF THE INVENTION

[0011] An object of the present application is to provide a composition, system, method and kit for removal of a detergent from an aqueous solution. The composition, system, method and kit may also be used for removal of detergent-associated or detergent-bound molecules, including proteins, from an aqueous solution.

[0012] In accordance with one aspect, there is provided a detergent removal system comprising: (a) a salt; (b) a water immiscible alcohol of Formula I



I

where R¹ is an optionally substituted, linear, branched or cyclic C₄ - C₁₂ alkyl; and (c) a water immiscible halocarbon, wherein the halocarbon is miscible with the alcohol.

Optionally, the salt is a quaternary ammonium salt or an alkali metal salt. In certain embodiments, the detergent is an anionic detergent. In certain embodiments, the system may also be used to remove detergent-associated and/or detergent-bound molecules that may be present in the aqueous solution.

[0013] In accordance with another aspect, there is provided a method of removing a detergent from an aqueous solution comprising said detergent, said method comprising the step of mixing the aqueous solution with: a salt; a water immiscible alcohol of Formula I




where R¹ is an optionally substituted, linear, branched or cyclic C₄ - C₁₂ alkyl; and a water immiscible halocarbon, wherein the halocarbon is miscible with the alcohol, to form a two-phase mixture, wherein substantially all of the detergent is in the non-aqueous phase. In certain embodiments, the detergent is an anionic detergent. In certain embodiments, the method may also be used to remove detergent-associated and/or detergent-bound molecules that may be present in the aqueous solution.

[0014] In accordance with another aspect, there is provided a biphasic composition formed from mixing: a salt; a water immiscible alcohol of Formula I



where R¹ is an optionally substituted, linear, branched or cyclic C₄ - C₁₂ alkyl; and a water immiscible halocarbon; with an aqueous solution comprising a detergent, wherein substantially all of the detergent is in the non-aqueous phase. In certain embodiments, the detergent is an anionic detergent. In certain embodiments, the non-aqueous phase of the biphasic composition may also comprise detergent-associated and/or detergent-bound molecules.

[0015] In accordance with another aspect, there is provided a kit for removal of a detergent from an aqueous solution comprising said detergent, said kit comprising: a salt; a water immiscible alcohol of Formula I



I

where R^1 is an optionally substituted, linear, branched or cyclic $C_4 - C_{12}$ alkyl; a water immiscible halocarbon, wherein said halocarbon is miscible with said alcohol of Formula I; at least one reagent container; and, optionally, instruction(s) for use. In certain embodiments, the detergent is an anionic detergent. In certain embodiments, the kit may also be used to remove detergent-associated and/or detergent-bound molecules from the aqueous solution that may be present.

[0016] The present composition, system, method and kit may, thus, ideally be used to remove inhibitors from aqueous solutions, i.e. inhibitors that inhibit reactions such as downstream applications, including, but not limited to, PCR (including RT-PCR), library preparation, and nucleotide sequencing. Inhibitors may include, for example, enzymatic inhibitors, e.g., inhibitors of enzyme-dependent reactions in subsequent applications, for example.

[0017] In certain embodiments, at least a portion of the aqueous phase (i.e., the phase that does not substantially contain the detergent, and detergent-associated or detergent-bound molecules, if present) may be used directly for downstream applications including, but not limited to, PCR (including RT-PCR), library preparation, and nucleotide sequencing.

BRIEF DESCRIPTION OF THE FIGURES

[0018] For a better understanding of the present invention, as well as other aspects and further features thereof, reference is made to the following description which is to be used in conjunction with the accompanying drawings, where:

[0019] Figure 1 depicts the treatment of 1% SDS in water solution with a detergent removal composition; composition 1 comprises a 1:1 mix of 1-pentanol and bromodichloromethane (BDCM) with 150 mM ammonium chloride (NH_4Cl); composition 2 comprises a 1:1 mix of 1-pentanol and chloroform with 150 mM NH_4Cl ; composition 3 comprises a 1:1 mix of 1-pentanol and 2-iodopropane with 150 mM NH_4Cl ;

[0020] Figure 2 depicts the treatment of 4% SDS in water solution with a detergent removal composition; all the compositions studied comprise a 1:1 mix of 1-pentanol and BDCM with

25 Feb 2026

2026201397

a salt as follows: Composition 4: 175mM of NH₄Cl, Composition 5: 200 mM of NH₄Cl; Composition 6: 125 mM of methyltri-n-butylammonium chloride; Composition 7: 150 mM of methyltri-n-butylammonium chloride; Composition 8: 150 mM of triethylamine hydrochloride; Composition 9: 175 mM of triethylamine hydrochloride; Composition 10: 175 mM of tetra-n-butylammonium acetate; Composition 11: 200 mM of tetra-n-propylammonium chloride;

[0021] Figure 3 depicts the treatment of 10% SDS in water solution with a detergent removal composition; all the compositions studied comprise a 1:1 mix of 1-pentanol and BDCM with varying concentrations of NH₄Cl as follows: Composition 12: 275 mM; Composition 13: 300 mM; and Composition 14: 325 mM and the resulting data demonstrates that, even at a starting concentration of 10%, the SDS could be reduced to <0.00625% in one step with 1/5th volume of the composition;

[0022] Figure 4 depicts the treatment of a saliva sample collected into an aqueous solution comprising 2% SDS with a detergent removal composition; the composition used comprised a 1:1 mix of 1-pentanol and BDCM with 125 mM ammonium chloride, which demonstrated efficient removal of SDS even in the presence of this biological sample;

[0023] Figure 5 depicts the treatment of a blood sample collected into an aqueous solution comprising 2.5% SDS with a detergent removal composition; the composition used comprised a 1:1 mix of 1-pentanol and BDCM with 175 mM ammonium chloride and the results showed that SDS was efficiently removed even in the presence of this complex biological sample;

[0024] Figure 6 depicts the results of qPCR carried out on aqueous solutions of known SDS concentrations: a control containing no SDS, and solutions of 0.001% SDS, 0.005% SDS, 0.01% SDS, 0.05% SDS; 0.1% SDS and 1% SDS were tested and compared and the results demonstrated that partial inhibition of qPCR occurred in the presence of 0.005% SDS and complete inhibition occurred when SDS was present at 0.01%;

[0025] Figure 7 is a photograph of an agarose gel stained with SybrGold™ (Invitrogen) following electrophoresis of an aliquot of the aqueous phase from a saliva sample collected into a detergent solution and treated with a detergent removal composition as described

herein; high molecular weight DNA can be seen in the sample lane alongside a 1 Kb+ DNA ladder, indicating that the detergent removal composition did not cause degradation of DNA;

[0026] Figure 8 shows the results of qPCR performed on an aliquot of the aqueous phase from a saliva sample collected into a detergent solution and treated with a detergent removal composition, alongside two standard controls of known amounts of DNA; the results demonstrate that DNA remaining in the aqueous phase after detergent removal treatment was suitable for use in qPCR;

[0027] Figure 9 is a photograph of an agarose gel stained with SybrGold™ (Invitrogen) following electrophoresis of an aliquot of the aqueous phase from a blood sample collected into a detergent solution and treated with a detergent removal composition; high molecular weight DNA can be seen in the sample lane alongside a 1 Kb+ DNA ladder, indicating that the detergent removal composition did not cause degradation of DNA;

[0028] Figure 10 shows the results of qPCR performed on two different sized aliquots of the aqueous phase from a blood sample collected into a detergent solution and treated with a detergent removal composition, alongside an aliquot from a control containing a known amount of DNA; the results show that DNA remaining in the aqueous phase after detergent removal treatment was suitable for use in qPCR;

[0029] Figure 11 is a photograph of an agarose gel stained with SybrGold™ (Invitrogen) following electrophoresis of an aliquot of the aqueous phase from a saliva sample collected into a detergent solution and treated with a detergent removal composition; bacterial 16S and 23S ribosomal RNA bands, originating from bacterial cells in saliva, can be seen on the gel, which indicates that bacterial RNA was not degraded by the detergent removal treatment;

[0030] Figure 12 shows the results of qPCR of the Reverse Transcriptase products prepared from a 1 µl aliquot of the aqueous phase taken from a saliva sample collected into a detergent solution and treated with a detergent removal composition;

[0031] Figure 13 shows the results of qPCR of the Reverse Transcriptase products prepared from a 3 µl aliquot of the aqueous phase taken from a saliva sample collected into a detergent solution and treated with a detergent removal composition;

[0032] Figure 14 is a photograph of an agarose gel stained with SybrGold™ (Invitrogen) following electrophoresis of an aliquot of the aqueous phase from a blood sample collected into a detergent solution and treated with a detergent removal composition; human 18S and 28S ribosomal RNA bands can be seen, indicating that human RNA was not degraded;

[0033] Figure 15 shows the results of qPCR of the Reverse Transcriptase products prepared from a 1 µl aliquot of the aqueous phase of a blood sample collected into a detergent solution and treated with a detergent removal composition;

[0034] Figure 16 is a photograph of a polyacrylamide gel stained with Coomassie blue to reveal protein bands following SDS-PAGE; aliquots of the same blood sample collected into a standard EDTA tube were removed and treated with various components of the detergent removal composition described herein: Lane 1 contains the protein molecular weight marker, Lane 2 is empty, Lane 3 contains 0.5 µl of lysed blood sample prior to detergent removal, Lane 4 is empty. Lane 5 contains 1 µl of lysed blood sample prior to detergent removal, Lane 6 is empty, Lane 7 contains 7.5 µl of aqueous phase after treatment of a lysed blood sample with BDCM only, Lane 8 is empty, Lane 9 contains 7.5 µl of aqueous phase after treatment of a lysed blood sample with a 3:7 (vol/vol) mix of 1-pentanol: BDCM, Lane 10 contains 7.5 µl of aqueous phase after treatment of a lysed blood sample with a 1:1 (vol/vol) mix of 1-pentanol: BDCM, Lane 11 contains 7.5 µl of aqueous phase after treatment of a lysed blood sample with a 7:3 (vol/vol) mix of 1-pentanol: BDCM, and Lane 12 contains 7.5 µl of aqueous phase after treatment of a lysed blood sample with 1-pentanol only.

[0035] Figure 17 depicts the treatment of a saliva sample collected into an aqueous solution comprising 2% Sarkosyl with a detergent removal composition; the detergent removal composition used comprised a 1:0.8 mix of 1-pentanol and (poly)chlorotrifluoroethylene with 200 mM ammonium chloride and the results show that Sarkosyl was efficiently removed even in the presence of this biological sample.

[0036] Figure 18 depicts the Bioanalyzer gel images of STAT- and prepIT·L2P-treated saliva samples from donor A (Figure 18A) and donor B (Figure 18B).

[0037] Figure 19 depicts the Bioanalyzer gel traces of the library preps constructed from saliva samples of 2 donors. Figure 19A depicts the trace of the library prep constructed from the saliva sample of donor A purified with Oragene/prepIT·L2P; Figure 19B depicts the trace

25 Feb 2026

2026201397

of the library prep constructed from the saliva sample of donor A treated with Oragene/STAT; Figure 19C depicts the trace of the library prep constructed from the saliva sample of donor B purified with Oragene/prepIT·L2P; and Figure 19D depicts the Bioanalyzer gel trace of the library prep constructed from the saliva sample of donor B treated with Oragene/STAT.

DETAILED DESCRIPTION

[0038] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0039] As used in the specification and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.

[0040] The term “comprising” as used herein will be understood to mean that the list following is non-exhaustive and may or may not include any other additional suitable items, for example one or more further feature(s), component(s) and/or ingredient(s) as appropriate.

[0041] The present application provides a system, method, composition and kit for removing a detergent (such as, for example, an anionic detergent or anionic surfactant) from an aqueous solution. The system, method, composition and kit may also be used for removing detergent-associated and/or detergent-bound molecules from the aqueous solution, if present. The present system and method effectively remove the detergent, and any detergent-associated/detergent-bound molecules present, to barely detectable levels by sequestering the detergent and detergent-associated/detergent-bound molecules, such as protein, into an organic layer. The result of mixing the aqueous solution with the composition is a two phase mixture comprising an upper aqueous phase substantially free of the detergent and any detergent-associated/detergent-bound molecules that may be present, and a lower, denser organic phase comprising the detergent, and any detergent-associated/detergent-bound molecules that may be present. The detergent removal composition consists of the following components: 1) a salt; 2) a water immiscible alcohol; and 3) a halocarbon.

[0042] As used herein, a detergent removal composition, detergent removal system, detergent removal method, and detergent removal kit, refer to compositions, systems, methods and kits

for the removal of a detergent and, if present, detergent-associated and/or detergent-bound molecules, from an aqueous solution. In certain embodiments, the detergent is an anionic detergent.

[0043] As would be understood by a worker skilled in the art, when the detergent, and detergent-associated/detergent-bound molecules present, are described herein as being “removed” from the aqueous solution, it is likely that some low concentration of detergent or detergent-associated/detergent-bound molecules remains in the aqueous solution. However, to be considered “removed”, the detergent and detergent-associated/detergent-bound molecule concentration in the aqueous solution will have dropped below a threshold detergent concentration selected based on the ultimate application of the aqueous solution. In one embodiment, following “removal” of the detergent (and detergent-associated/detergent-bound molecules, if present) using the present system, composition, method and kit, the concentration of detergent (and detergent-associated/detergent-bound molecules, if present) in the aqueous solution is below a detectable concentration using the Stains-All Assay described in Example 1.

[0044] In certain embodiments, a “detergent”, as used herein, includes detergents which include, but are not limited to, an anionic detergent, for example. Non-limiting examples of anionic detergents that can be removed from an aqueous solution using the present detergent removal system, method, composition, and kit are sodium dodecyl sulfate (SDS) and Sarkosyl.

[0045] Detergent Removal Composition and System

[0046] As noted above, the detergent removal composition and system described herein contain at least three components: a salt; a water immiscible alcohol; and a halocarbon. These components can be maintained separately until they are mixed with the aqueous solution for detergent removal, or they can be combined and stored together as a mixture of all three components, or any two of the three components, prior to being used in removing detergent (and detergent-associated/detergent-bound molecules, if present) from an aqueous solution. As such, the present detergent removal system can further comprise one or more containers for storing the salt; water immiscible alcohol; and halocarbon components prior to use.

[0047] The present composition and system may, thus, ideally be used to remove inhibitors from aqueous solutions, i.e., inhibitors that inhibit reactions such as downstream applications, including, but not limited to, PCR (including RT-PCR), library preparation, and nucleotide sequencing. Inhibitors may include, for example, enzymatic inhibitors, i.e., inhibitors of enzyme-dependent reactions in subsequent applications, for example.

[0048] In certain embodiments, at least a portion of the aqueous phase (i.e., the phase that does not substantially contain the detergent, and detergent-associated or detergent-bound molecules, if present) may be used directly for downstream applications including, but not limited to, PCR (including RT-PCR), library preparation, and nucleotide sequencing.

[0049] Salt component

[0050] Salts useful in the present system, composition and method are quaternary ammonium salts or alkali metal salts. Specific examples of salts that can be used in the present system, composition and method include, but are not limited to, ammonium acetate, ammonium chloride, ammonium sulfate, a betaine salt, choline chloride, diethylamine hydrochloride, dimethylethanolamine, ethanolamine, ethylammonium chloride, methylammonium chloride, tetra-n-butylammonium acetate, tetraethylammonium chloride monohydrate, tetramethylammonium chloride, tetra-n-propylammonium chloride, methyltri-n-butylammonium chloride, triethylamine hydrochloride, triethylmethylammonium chloride, trimethylamine hydrochloride, an acid salt of 1-butylamine, an acid salt of 1-pentylamine, an acid salt of 1-hexylamine, an acid salt of 1-dodecylamine, lithium chloride; sodium chloride, potassium chloride, and combinations thereof.

[0051] Alcohol component

[0052] The present system and method takes advantage of the change in solubility characteristic of the detergent, such as an anionic detergent, when an aqueous solution comprising the detergent is mixed with the present detergent removal composition. In order to facilitate the formation of a two-phase mixture, the alcohol component must be immiscible or only sparingly miscible in water. The water immiscible alcohol has the structure of Formula I



2026201397 25 Feb 2026

where R¹ is an optionally substituted, linear, branched or cyclic C₄ - C₁₂ alkyl.

[0053] Examples of water immiscible alcohols useful in the present systems, methods and compositions for detergent removal include, but are not limited to, 1-butanol, 3-methyl-1-butanol, 2-butanol, 1-heptanol, 1,2-hexanediol, 1-hexanol, 2-nonanol, 1-pentanol, 4-methyl-2-pentanol, cyclopentanol, 1-undecanol or combinations thereof.

[0054] Halocarbon Component

[0055] One of the functions of the halocarbon component is to increase the density of the organic phase in the two phase mixture that forms on mixing an aqueous solution with the present detergent removal composition, such that the organic phase is the bottom phase and the aqueous phase is the upper phase. Furthermore, to ensure good separation of the two phases, the halocarbon must be immiscible or only sparingly miscible with water and must be miscible with the alcohol component.

[0056] Examples of halocarbons that are useful in the present systems, methods and compositions for detergent removal include, but are not limited to, 1-bromo-3-chloropropane, 1-bromo-6-chlorohexane, bromodichloromethane (BDCM), chlorodibromomethane, chloroform, 2-iodopropane, (poly)chlorotrifluoroethylene (-(CF₂CFCl)_n- where n=2 to 10; specifically the halocarbon oil 6.3 obtained from Halocarbon Products Corporation, River Edge, NJ; CAS#9002-83-9), or a combination thereof. Perfluorononane is an example of a halocarbon that did not function well in the present detergent removal composition. Without wishing to be bound by theory, this is likely due to the fact that the perfluorononane was not miscible with the alcohol component.

[0057] Optional components

[0058] The present system and composition can optionally contain additional components depending on, for example, the nature of the aqueous solution containing the detergent to be removed, or the ultimate application of the aqueous solution following detergent removal (and removal of detergent-associated or detergent-bound molecules, if present).

[0059] In one embodiment, the detergent removal system additionally comprises glass beads, which can function to improve and/or speed up the lysis of cells present in the aqueous sample or improve mixing of the aqueous solution comprising the detergent with the salt,

25 Feb 2026

2026201397

alcohol and halocarbon components. Without being limited by theory it is believed that when a raw sample (e.g. saliva) is vigorously mixed concurrently with SDS and the composition of the present invention, the beads help to homogenize the sample, lyse the cells and bring SDS into contact with protein-bound DNA. SDS then strips the protein from the DNA and the composition segregates the SDS and SDS-associated/SDS-bound molecules to the organic phase.

[0060] In another embodiment, the detergent removal system additionally comprises a reducing agent. A reducing agent can also be present in, or added to, the aqueous solution containing the detergent to be removed, before mixture with the present detergent removal composition. Such a reducing agent can be, for example, dithiothreitol (DTT), mercaptohexanol, mercaptoundecanol, dimercaptopropanol or mercaptobutanol.

[0061] In yet another embodiment, the detergent removal system additionally comprises a chelator and/or a buffer. A chelator and/or a buffer can also be present in, or added to, the aqueous solution containing the detergent to be removed, before mixture with the present detergent removal composition. Such a chelator agent can be, for example, ethylene glycol tetraacetic acid (EGTA), (2-Hydroxyethyl)ethylenediaminetriacetic acid (HEDTA), diethylene triamine pentaacetic acid (DTPA), NitriLoTriAcetic Acid (NTA), ethylenediaminetriacetic acid (EDTA), cyclohexanediaminetetraacetic acid (CDTA), citrate anhydrous, sodium citrate, calcium citrate, ammonium citrate, ammonium bicitrate, citric acid, diammonium citrate, ferric ammonium citrate, lithium citrate, or any combination thereof. Any suitable buffer may be used and are well known to those in the art.

[0062] In another embodiment, the detergent removal system additionally comprises a lipophilic stain, such as Nile Red. Nile Red stains intracellular lipid, cell membranes and hydrophobic protein surfaces. When mixed with a biological sample and the present composition the stain partitions exclusively to the lower organic phase, leaving the upper aqueous phase clear and colourless. Such a lipophilic stain can be, for example, 9-Anthryldiazomethane, Fluorol Yellow 088, N,N,N-Trimethyl-4-(6-phenyl-1,3,5-hexatrien-1-yl) phenylammonium p-toluenesulfonate (TMA-DPH), 3,3'-Dioctadecyloxycarbocyanine perchlorate, 1,6-Diphenyl-1,3,5-hexatriene, Sudan III, Sudan Orange G, Nile Blue chloride and Solvent Blue 37.

[0063] Method of Detergent Removal

[0064] The present application provides a method of removing a detergent from an aqueous solution. In certain embodiments, the detergent is an anionic detergent. In certain embodiments, the anionic detergent is SDS or Sarkosyl. The present method may also be used to remove detergent-associated or detergent-bound molecules that may be present in the aqueous solution. The present method may, thus, ideally be used to remove inhibitors from aqueous solutions, i.e. inhibitors that inhibit reactions such as downstream applications, including, but not limited to, PCR (including RT-PCR), library preparation, and nucleotide sequencing. Inhibitors may include, for example, enzymatic inhibitors, e.g., inhibitors of enzyme-dependent reactions in subsequent applications, for example.

[0065] Simply, the method comprises mixing an aqueous solution comprising the detergent to be removed, with a salt, a water immiscible alcohol, and a halocarbon. The three components can be mixed with the aqueous solution in a single step or in multiple steps. The order of addition is not important; rather it is important that the components of the detergent removal composition are well mixed with the aqueous solution. This mixing step can include mechanical agitation, such as vortexing, to improve or facilitate mixing.

[0066] The aqueous solution can be any aqueous solution that contains a detergent to be removed. In certain embodiments, the detergent is an anionic detergent. In certain embodiments, the detergent is SDS or Sarkosyl. The aqueous solution may also contain detergent-associated and/or detergent-bound molecules. Such a solution can be, for example, a biological sample, such as saliva, sputum, buccal swab sample, serum, plasma, blood, pharyngeal, nasal/nasal pharyngeal or sinus swabs or secretions, throat swabs or scrapings, urine, mucous, feces, chyme, vomit, gastric juices, pancreatic juices, gastrointestinal juices, semen/sperm, cerebral spinal fluid, products of lactation or menstruation, egg yolk, amniotic fluid, aqueous humour, vitreous humour, cervical secretions or swabs, vaginal fluid/secretions/swabs or scrapings, bone marrow aspirates, pleural fluid, sweat, pus, tears, lymph, bronchial or lung lavage or aspirates, cell cultures and cell suspensions, connective tissue, epithelium, mucosal membrane, muscle tissue, placental tissue, organ tissue, nerve tissue, hair, skin, nails, plants, plant extracts, algae, microorganisms, soil samples, sewage, wastewater, foodstuff, or the like.

[0067] When the sample includes cells or tissue, it is beneficial to ensure good mixing with the detergent removal composition in order to maximize detergent removal. In one embodiment, glass beads or other mechanical means are added before or during mixing to facilitate sample dispersion and cell lysis. Alternatively, a tissue sample may be homogenized by mechanical or chemical means or digested with enzymes (e.g. Proteinase K) before or after mixing with SDS and the detergent removal composition. Alternatively, SDS alone may be able to lyse sufficient number of cells covering the surface of a solid piece of tissue (e.g. muscle biopsy or tumour biopsy), releasing nucleic acids into solution, subsequently treated with the detergent removal composition and used in downstream applications.

[0068] The biological samples may or may not also contain microorganisms, such as viruses, bacteria, yeast, fungi, archaea, and protists.

[0069] After full mixing of the aqueous solution with the detergent removal composition the resulting mixture is allowed to settle or is briefly centrifuged to form two phases. The detergent (and any detergent-associated or detergent-bound molecules) will be partitioned in the lower organic phase leaving the upper aqueous phase substantially free of the detergent. The top aqueous phase can be readily isolated by standard means, such as decanting or pipetting for downstream analysis without contamination from the lower organic phase.

[0070] This method is not only effective in removing a detergent, such as an anionic detergent, from the aqueous solution, but also in removing detergent-associated, or -bound, molecules and macromolecules. In a specific embodiment, the detergent-associated or -bound molecules are proteins. Anionic detergents, such as SDS, are known to lyse cells in a biological sample by disrupting the membrane lipid bilayer and denaturing proteins. Since SDS effectively solubilizes and binds tightly to proteins, it is believed the present detergent removal method and system can readily remove and isolate both the detergent and the detergent-associated/bound proteins into the lower organic phase. Accordingly, the present application further provides a method of extracting proteins from an aqueous solution, such as a biological sample. Thus, the method, composition, system and kit as described herein may ideally be used to remove inhibitors from aqueous solutions, i.e., inhibitors that inhibit reactions such as downstream applications including, but not limited to, PCR (including RT-PCR), library preparation, and nucleotide sequencing. Inhibitors may include, for example,

enzymatic inhibitors, e.g., inhibitors of enzyme-dependent reactions in subsequent applications, for example.

[0071] At least a portion of the aqueous phase (i.e., the phase that does not substantially contain the detergent, and detergent-associated or detergent-bound molecules, if present) may then be used directly for downstream applications including, but not limited to, PCR (including RT-PCR), library preparation, and nucleotide sequencing.

[0072] Also provided herein are kits for detergent removal. The kits include the salt, alcohol and halocarbon components of the detergent removal composition, in a single container or in two or three separate containers. Optionally the kit also includes instructions for performing the present detergent removal method and/or a sample collection container and/or a sample collection container containing a detergent solution. As stated above, in certain embodiments, the kit may also be used to remove detergent-associated and/or detergent-bound molecules from the aqueous solution that may be present.

[0073] To gain a better understanding of the invention described herein, the following examples are set forth. It should be understood that these examples are for illustrative purposes only. Therefore, they should not limit the scope of this invention in any way.

EXAMPLES

[0074] EXAMPLE 1: Sensitive Assay System for Detecting Low Concentrations of SDS

[0075] A sensitive assay system was developed to quantify very small (<0.01% wt/vol) amounts of SDS in samples. The quantification of SDS in this assay is based on the use of the 3,3'-diethyl-9-methyl-4,5,4',5'-dibenzothiacarbocyanine dye, also known as Stains-All. This is a fuchsia dye that turns yellow in the presence of SDS. The assay allows for the accurate detection and quantification of as little as 0.003% SDS in a sample.

[0076] The assay was adapted from the one described by Rusconi *et al.* in "Quantification of Sodium Dodecyl Sulfate in Microliter-Volume Biochemical Samples by Visible Light Spectroscopy." *Analytical Biochemistry*. 2001. 295, 31-37.

[0077] Equipment

- Tecan Infinite 200 Plate Reader

- Grenier 96 well Flat Bottom Transparent Polystyrol Plate

[0078] Reagents

- Stains-All [Sigma-Aldrich, Cat. No. E9379-1G]
- Isopropanol [EMD, Cat. No. PX1834-6]
- DMSO [BDH, Cat. No. B10323]
- 10% SDS (w/v) [EMD, Cat. No. DX2490-2]
 - o Diluted to 1% in H₂O prior to carrying out the assay

[0079] Preparation of Solutions

- Stains-All Stock Solution (1.8 mM) comprised of 1 mg/mL in 50% (v/v) isopropanol. This stock solution is stable at 4°C for 1 month in the dark.
- Stains-All Intermediate Solution (90 µM):
 - The intermediate solution was prepared by mixing 1 mL Stains-All Stock Solution (1.8 mM) with 1 mL DMSO and 18 mL H₂O. This Stains-All Intermediate Solution is stable for 3 days when stored at room temperature in the dark.

[0080] Preparation of SDS Standard Curve: The standard curve was prepared using the following standard solutions:

- a. 0.05% SDS = 5 µl 1% SDS + 95 µl H₂O
- b. 0.025% SDS = 50 µl (A) + 50 µl H₂O
- c. 0.0125% SDS = 50 µl (B) + 50 µl H₂O
- d. 0.00625% SDS = 50 µl (C) + 50 µl H₂O
- e. 0.003125% SDS = 50 µl (D) + 50 µl H₂O
- f. 0.0015625% SDS = 50 µl (E) + 50 µl H₂O
- g. 0.00078125% SDS = 50 µl (F) + 50 µl H₂O
- h. 0% SDS = H₂O

[0081] Procedure

1. Transfer 5 µl of either SDS standard solution or a sample to a well of a 96 well plate

2. Add 195 μ l of Stains-All Intermediate Solution to each sample immediately before reading absorbance (Note: Stains-All is light sensitive).
3. Read absorbance from 420 nm–480 nm using a standard plate reader.
4. Calculate absorbance ‘Area Under the Curve’ (AUC) (420-480 nm) using GraphPad Prism 5 software.

[0082] The standard curve (represented by the dark bars on the graphs) was prepared by plotting the AUC against the known SDS concentrations. The concentration of SDS in unknown samples was then readily obtained using the calculated AUC and the standard curve. Unless otherwise indicated, this method was used in determining SDS concentration in the following Examples.

[0083] EXAMPLE 2: Comparison of Detergent Removal Compositions

[0084] Various detergent removal compositions of the present invention were used to remove SDS from aqueous solutions containing known amounts of SDS. One hundred microlitre aliquots of the aqueous compositions containing different concentrations of SDS were prepared. SDS removal was carried out by adding a salt and 20 μ l of a 1:1 (vol/vol) mixture of a higher alcohol and halocarbon as described below. The tubes were vortexed vigorously for 2 minutes and centrifuged at 13,000 rpm for 2 minutes. The top (aqueous) phase was removed and residual SDS in the aqueous phase was quantified using the modified Stains-All Assay described in Example 1. The results are shown in Figures 1 to 3. The dark bars represent the SDS standard solutions, whereas white bars represent results from the tested detergent removal compositions.

[0085] The graph shown in Figure 1 depicts the results of an experiment in which an aqueous solution comprising 1% SDS was treated with various detergent removal compositions. Composition 1 comprises a 1:1 mix of 1-pentanol and bromodichloromethane (BDCM) with 150mM ammonium chloride (NH_4Cl). Composition 2 comprises a 1:1 mix of 1-pentanol and chloroform with 150mM NH_4Cl . Composition 3 comprises a 1:1 mix of 1-pentanol and 2-iodopropane with 150mM NH_4Cl . In each case, the amount of SDS detected in the aqueous phase following treatment was less than 0.00625% and, when the halocarbon used was 2-iodopropane, the amount of SDS detected following detergent removal was less than

0.003125%. This demonstrates a remarkably efficient (>99.7%) extraction of SDS from the aqueous phase in a single treatment using only one-fifth volume of the detergent removal composition.

[0086] The graph shown in Figure 2 depicts the results of an experiment in which an aqueous solution comprising 4% SDS was treated with various detergent removal compositions. In this study all compositions comprised a 1:1 mix of 1-pentanol and BDCM with a salt as follows: Composition 4: 175mM of NH₄Cl, Composition 5: 200mM of NH₄Cl; Composition 6: 125mM of methyltri-n-butylammonium chloride; Composition 7: 150mM of methyltri-n-butylammonium chloride; Composition 8: 150mM of triethylamine hydrochloride; Composition 9: 175mM of triethylamine hydrochloride; Composition 10: 175mM of tetra-n-butylammonium acetate; Composition 11: 200mM of tetra-n-propylammonium chloride. In each case, the amount of SDS detected in the aqueous phase following treatment was less than 0.00625%. Again, the results demonstrate a remarkably efficient (up to >99.9%) extraction of SDS from the aqueous phase in a single treatment using only one-fifth volume of the detergent removal composition.

[0087] The graph shown in Figure 3 depicts the results of an experiment in which an aqueous solution comprising 10% SDS was treated with various detergent removal compositions. In this study all compositions comprise a 1:1 mix of 1-pentanol and BDCM with varying concentrations of NH₄Cl as follows: Composition 12: 275mM; Composition 13: 300mM; and Composition 14: 325mM. In each case, the amount of SDS detected in the aqueous phase following treatment was less than 0.00625%. Once again, the results demonstrated a highly efficient (up to >99.9%) extraction of SDS from the aqueous component in a single treatment using only one-fifth volume of the detergent removal reagent, even at a very high (10% wt/vol) initial SDS concentration.

[0088] EXAMPLE 3: Removal of SDS from a Saliva-containing Sample

[0089] To demonstrate the effectiveness of the present invention in an aqueous composition containing a biological sample, a fresh human saliva sample was collected in a 15 ml conical tube. One milliliter of saliva was treated with an equal volume of lysis buffer containing 4% SDS and 250mM LiCl and digested with Proteinase K ("PK") at 60°C for 15 minutes. PK was inactivated by heating at 90°C for 15 minutes and a 93.75 µl aliquot of the treated saliva in lysis buffer was mixed with 6.25 µl of a 2 M ammonium chloride solution.

[0090] Detergent removal was carried out by adding 20 μ l of a 1:1 mixture of 1-pentanol and BDCM to 100 μ l of the treated saliva sample. The tube was vortexed vigorously for 2 minutes and centrifuged at 13,000 rpm for 2 minutes. The top (aqueous) phase was removed and SDS was quantified using the modified Stains-All Assay described in Example 1. The results are shown in Figure 4. These results demonstrate the successful removal of >99.7% of the SDS from a saliva-containing aqueous sample using the composition and procedure described herein.

[0091] EXAMPLE 4: Removal of SDS from a Venous Blood-derived Sample

[0092] To demonstrate the effectiveness of the present invention in an aqueous composition containing a complex biological sample, human venous blood was collected in EDTA tubes. One millilitre of blood was lysed in three volumes of a lysis buffer containing SDS and ammonium chloride at 70°C for 15 minutes. The final concentrations of SDS and ammonium chloride in the lysed blood sample were 2.5% and 175mM, respectively.

[0093] Detergent removal was carried out on 100 μ l of lysed blood sample by adding 20 μ l of a 1:1 mixture of pentanol and BDCM. The tubes were vortexed vigorously for 2 minutes and centrifuged at 13,000 rpm for 2 minutes. The top (aqueous) phase was removed and SDS was quantified using the modified Stains-All Assay described in Example 1. The results, shown in Figure 5, demonstrated that SDS can be successfully removed (>99%), even from a complex biological sample such as venous blood.

[0094] EXAMPLE 5: Inhibition of PCR by Various Concentrations of SDS

[0095] Multiple qPCR reactions were carried out using the following master mix: 2.5 μ l of 1mg/ml bovine serum albumin (BSA), 2.5 μ l of 10x PCR Buffer, 1.5 μ l of 50mM MgCl₂, 0.5 μ l of 10mM dNTPs, 0.5 μ l of 10 pMol forward primer, 0.5 μ l of 10 pMol reverse primer (human 18S-165 forward 5' gtggagcgattgtctggtt and human 18S-165 reverse 5' ggacatctaagggcatcacag) 0.5 μ l of 0.5 μ M Syto 9, 0.2 μ l of 5U/ μ l Taq Polymerase, 12.3 μ l of water.

[0096] qPCR reactions with known amounts of control DNA and varying concentrations of SDS ranging from 1% to 0.001% wt/vol were carried out using the 18S rRNA gene, a 57.4°C primer annealing temp and 30 cycles.

[0097] Results are presented in Figure 6 demonstrating that qPCR was completely inhibited at concentrations of SDS as low as 0.01% with partial inhibition observable at 0.005%. These ranges are in agreement with the published data referred to above.

[0098] EXAMPLE 6: Use of DNA in Biological Samples for qPCR Following Detergent Removal

[0099] Saliva-derived sample

[00100] The aqueous phase of a lysed saliva sample was obtained after treatment with the detergent removal compositions, as described in Example 3. A 12 μ l aliquot of the aqueous phase was electrophoresed in a 1% agarose gel alongside a 1 Kb⁺ DNA ladder; the gel was then stained with SybrGold™ (Invitrogen, Cat # S11494). Results are presented in Figure 7 where high molecular weight DNA (>23Kb) can be seen, thus demonstrating that treatment with the composition of the present invention leaves the DNA intact and in the aqueous phase.

[00101] qPCR was performed using an aliquot of the aqueous phase following detergent removal according to the method described in Example 5 above. Data for 4 μ l of saliva-derived aqueous phase directly added to total of 25 μ l of the qPCR reaction is shown in Figure 8. For comparison, 5ng and 50ng of purified DNA was also subjected to qPCR for the 18S rRNA gene.

[00102] These results provided further demonstration that SDS could be efficiently and rapidly removed from a saliva-derived aqueous sample, following the detergent removal procedure described above. The data obtained in Figure 8, showing successful qPCR implies that the saliva-derived aqueous phase contains only very low amounts of residual PCR inhibitors. Possibly, the use of a smaller aliquot in a larger volume of qPCR mixture could give similar results. In fact, dilution is a common approach to dealing with inhibitors naturally present in blood samples. However, this approach would result in a loss of total DNA obtainable from a sample and would introduce more sources of error in the experimental method. It is always preferable to have the ability to use larger and more concentrated samples. The presently described method and composition allows the use of samples without the need to use a high dilution approach.

[00103] Blood-derived sample

[00104] The aqueous phase for this example was obtained after detergent removal from a lysed blood sample as described in Example 4. An 8 μ l aliquot of the aqueous phase following detergent removal was electrophoresed in a 0.8% agarose gel alongside a 1Kb⁺ DNA ladder, following which the gel was stained with ethidium bromide. Results are presented in Figure 9 where high molecular weight DNA (>23Kb) can be seen, thus demonstrating that treatment with the composition of the present invention leaves the DNA intact and in the aqueous phase.

[00105] qPCR as described in Example 5 above was performed using an aliquot of the aqueous phase following detergent removal. Data for both a 2 μ l and a 4 μ l of blood-derived aqueous phase directly added to give a total of 25 μ l of qPCR reaction is shown in Figure 10.

[00106] These results provided further demonstration that SDS was effectively removed from the blood-derived aqueous sample, following the detergent removal procedure described above. Since blood is known to contain significant amounts of PCR inhibitors, the data of Figure 10 is quite remarkable in that high dilution of the sample was not required once the SDS-containing blood sample was treated with the detergent removal composition as described in Example 4. As is demonstrated below, not only was SDS removed from the sample, but any SDS-associated protein was also removed and may potentially explain this remarkable result.

[00107] EXAMPLE 7: Use of RNA from Biological Samples for Reverse Transcriptase (RT)-PCR Following Detergent Removal

[00108] Saliva

[00109] Two mL of a fresh saliva sample was collected in a 15ml conical tube and mixed with an equal volume of a lysis buffer (4% SDS, 250mM LiCl).

[00110] A 200 μ l aliquot of the lysed saliva was mixed with PK and incubated at 60°C for 15 minutes. The PK was then inactivated by heating at 90°C for 15 minutes. 10 μ l of 2 M ammonium chloride and 40 μ l of a 1:0.8 (vol/vol) mixture of 1-pentanol and (poly)chlorotrifluoroethylene were added. The tube was vortexed vigorously for 2 minutes and centrifuged at 13,000 rpm for 2 minutes. The top (aqueous) phase was removed and

25 Feb 2026

2026201397

electrophoresed in 1% agarose gel. The gel was treated with SybrGold to stain the nucleic acids (Figure 11). Bacterial 16S and 23S ribosomal RNA bands were seen demonstrating that the detergent removal composition described herein left RNA intact in the aqueous phase. No human 28S and 18S ribosomal RNA bands were seen because they are present in very small amounts in saliva, too low to be detected by staining with SybrGold. However, human ribosomal RNA can be detected by RT-PCR, as shown in the next section.

[00111] The aqueous phase derived from a saliva sample was treated as described above, except that a 1:1 (vol/vol) mixture of BDCM and 1-pentanol was used as a detergent removal composition. One μl of saliva aqueous phase was directly added to 20 μl RT reaction mixture (4 μl 5X First Strand Buffer (Invitrogen), 2 μl 100 mM DTT, 2 μl 10 mM dNTPs, 2 μl 50 mM MgCl_2 , 1 μl RNase Inhibitor (10 U/ μl), 1 μl random primers (125 ng/ μl , Invitrogen), 2 μl M-MLV reverse transcriptase (Invitrogen), water for the remaining volume). One μl of the RT product was then added to 24 μl of qPCR reaction and processed as described in Example 5 above, probing for human 18S ribosomal RNA cDNA. A negative control tube (without RT enzyme) was labeled as –RT. Results are shown in Figure 12.

[00112] A separate fresh saliva sample was processed exactly as described above. The top aqueous phase was removed and 3 μl was directly added to 18 μl RT reaction mixture (described above). Two μl of the RT product was then added to 23 μl of qPCR reaction and processed as described in Example 5 above, probing for human 18S ribosomal RNA cDNA. A negative control tube (without reverse transcriptase enzyme) is labeled as –RT. Results are shown in Figure 11. In both cases (Figures 12 and 13), the results show that human 18S ribosomal RNA could be detected in the aqueous phase of a lysed saliva sample treated with the detergent removal composition. As expected, the use of 3 μl in the RT reaction and 2 μl in the qPCR reaction (Figure 13), instead of 1 μL and 1 μL , respectively (Figure 12), produced more 18S ribosomal RNA cDNA in the RT reaction, as evidenced by the lower Ct value in the PCR reaction. The significant increase in RT product, and consequently qPCR product, with larger volumes of aqueous phase demonstrated the remarkable effectiveness of the detergent removal composition in the segregation of inhibitors to the lower organic phase. The –RT signal was due to the presence of human genomic DNA, which was not removed in these studies.

[00113] Blood

[00114] Human venous blood was collected in standard EDTA tubes. One volume of blood was mixed with 9 volumes of lysis buffer (4% SDS, 250 mM LiCl). Lysed blood was digested with PK at 60°C for 15 min; PK was then inactivated at 90°C for 15 minutes. Removal of the SDS from a 100 µl aliquot of lysed blood was carried out by mixing 5 µl 2M ammonium chloride and 20 µl of a 1:0.8 (vol/vol) mixture of 1-pentanol and (poly)chlorotrifluoroethylene. The tube was vortexed vigorously for 2 minutes and centrifuged at 13,000 rpm for 2 minutes. The top (aqueous) phase was removed and an aliquot run in 1% agarose gel (Figure 14). The nucleic acids were stained with SybrGold. Bands corresponding to human 18S and 28S ribosomal RNA can be seen. One µl of blood aqueous phase was added to 20 µl RT reaction mixture (4 µl 5X First Strand Buffer (Invitrogen), 2 µl 100mM DTT, 2 µl 10mM dNTPs, 2 µl 50 mM MgCl₂, 1 µl RNase Inhibitor (10 U/µl), 1 µl random primers (125ng/µl, Invitrogen), 1.5 µl M-MLV reverse transcriptase (Invitrogen), water for the remaining volume). One µl of RT product was then added to 24 µl of qPCR reaction and processed as described in Example 5 above. Negative control tube without reverse transcriptase enzyme is labeled as –RT. Results, shown in Figure 15, clearly demonstrated that, once SDS, with potentially additional inhibitors bound to SDS, was removed by the detergent removal composition, human 18S ribosomal RNA could be detected by RT-PCR.

[00115] EXAMPLE 8: Comparison of Alcohols

[00116] Several representative alcohols were investigated for their ability to perform in the detergent removal composition. Primary alcohols, secondary alcohols, cyclic alcohols, diols and both solid and liquid alcohols (at room temperature) were tested. Alcohols were tested either on a raw biological sample and/or in a “model system” whereby a simple water and SDS (4% wt/vol) mixture was used. In order to have effective phase separation the alcohol must be largely immiscible in water yet be soluble with the halocarbon. Results are summarized as follows:

[00117]

Alcohol	Halocarbon	Salt	Sample Type	Result
1-propanol	BDCM	NH ₄ Cl	Model System	No phase separation
1,2-propanediol	BDCM	NH ₄ Cl	Blood	No phase separation

Alcohol	Halocarbon	Salt	Sample Type	Result
1-butanol	BDCM	NH ₄ Cl	Blood	Separation with clear aqueous phase; successful qPCR
3-methyl-1-butanol	BDCM	NH ₄ Cl	Blood	Separation with clear aqueous phase
1-pentanol	BDCM	NH ₄ Cl	i) Model system; ii) Blood	i) Separation with clear aqueous phase ii) Separation with clear aqueous phase; successful qPCR
4-methyl-2-pentanol	BDCM	NH ₄ Cl	Blood	Separation with clear aqueous phase
Cyclopentanol	BDCM	NH ₄ Cl	Blood	Separation with clear aqueous phase, successful qPCR
1,2-hexanediol	BDCM	NH ₄ Cl	Blood	Separation with clear aqueous phase
1-hexanol	BDCM	NH ₄ Cl	Blood	Separation with clear aqueous phase; successful qPCR
1-heptanol	Poly(chlorotrifluoroethylene)	NH ₄ Cl	Blood	Separation with clear aqueous phase
2-nonanol	BDCM	NH ₄ Cl	i) Model System ii) Blood	i) Separation with clear aqueous phase ii) Separation with clear aqueous phase; successful qPCR
1-undecanol	BDCM	NH ₄ Cl	Blood	Separation achieved with increased salt concentration resulting in clear aqueous phase
1-tetradecanol	BDCM	NH ₄ Cl	Blood	Separation achieved with increased salt concentration resulting in cloudy aqueous phase. This was considered an unsatisfactory result.

[00118] As can be inferred from the observations obtained above, the water immiscible alcohol can be any alcohol with the structure of Formula I



where R¹ is an optionally substituted, linear, branched or cyclic C₄ - C₁₂ alkyl.

[00119] EXAMPLE 9: Removal of Protein from an Aqueous Sample

[00120] Human venous blood was collected in a standard EDTA tube. One volume of blood was mixed thoroughly with 3 volumes of lysis buffer containing 4% SDS and 30 mM DTT. Detergent and protein removal was carried out as follows. NH₄Cl was added to a final concentration of 100 mM to 100 µl aliquots of the lysed blood sample. To each aliquot of

lysed blood was added 20 μ l of detergent removal composition containing varying amounts of 1-pentanol and BDCM (see details below). The tubes were vortexed vigorously for 2 minutes and centrifuged at 13,000 rpm for 2 minutes. The initial lysed blood samples (i.e., prior to detergent removal), as well as aqueous phases after detergent removal, were analysed by SDS-PAGE. The polyacrylamide gels were stained with Coomassie blue to reveal the protein bands. Results are shown in Figure 16. Lane 1 contains the protein molecular weight marker. Lane 2 is empty. Lane 3 contains 0.5 μ l of lysed blood sample prior to detergent removal. Lane 4 is empty. Lane 5 contains 1 μ l of lysed blood sample prior to detergent removal. Lane 6 is empty. Lane 7 contains 7.5 μ l of aqueous phase after treatment of lysed blood sample with BDCM only. Lane 8 is empty. Lane 9 contains 7.5 μ l of aqueous phase after treatment of a lysed blood sample with a 3:7 (vol/vol) mix of 1-pentanol: BDCM. Lane 10 contains 7.5 μ l of aqueous phase after treatment of a lysed blood sample with a 1:1 (vol/vol) mix of 1-pentanol: BDCM. Lane 11 contains 7.5 μ l of aqueous phase after treatment of a lysed blood sample with a 7:3 (vol/vol) mix of 1-pentanol: BDCM. Lane 12 contains 7.5 μ l of aqueous phase after treatment of lysed blood sample with 1-pentanol only.

[00121] The results show that very little or no protein was present in Lanes 9, 10 and 11 where the samples were treated with the detergent removal composition. This remarkably efficient extraction of proteins is very surprising. It shows that as little as 1/5th volume of the detergent removal composition (i.e., 20 μ l added to 100 μ l of lysed blood sample) can very effectively remove the vast majority of protein from blood. The removal of the dark red color of hemoglobin that was observed (data not shown) is another indication of the unexpectedly powerful deproteinizing power of the detergent removal composition for samples containing SDS. The protein bands visible in lanes 3, 5, 7 and 12, where the detergent removal composition of the present application was not used (lanes 3 and 5) or some component was left out (lanes 7 and 12), indicates that all three components are essential for good results.

[00122] Example 10: Removal of Sarkosyl from a Biological Sample and Use of DNA in qPCR

[00123] To demonstrate the effectiveness of the present method and composition for detergent removal in an aqueous composition containing a biological sample, a fresh human saliva sample was collected in a 15 ml conical tube. One milliliter of saliva was treated with

an equal volume of lysis buffer containing 4% Sarkosyl and digested with Proteinase K (“PK”) at 60°C for 15 minutes. PK was inactivated by heating at 90°C for 15 minutes and a 90 µl aliquot of the treated saliva in lysis buffer was mixed with 10.00 µl of a 2 M ammonium chloride solution.

[00124] Detergent removal was carried out by adding 20 µl of a 1:0.8 mixture of 1-pentanol and (poly)chlorotrifluoroethylene to 100 µl of the treated saliva sample. The tube was vortexed vigorously for 2 minutes and centrifuged at 13,000 rpm for 2 minutes. The top (aqueous) phase was removed and 4 µl was added to a human18s-165bp PCR reaction according to the method described in Example 5 above. Data for 4 µl of saliva-derived aqueous phase directly added to total of 25 µl of the qPCR reaction is shown in Figure 17.

[00125] Example 11: Use of DNA in Biological Samples for the Construction of Library Preps Following Detergent Removal.

[00126] A key element of next-generation sequencing (NGS) is high-quality library preparation. The majority of high-throughput NGS library construction workflows depend upon a common series of steps, some of which are accomplished enzymatically – DNA fragmentation, end repair, A-tailing, adapter ligation, and PCR amplification. Input DNA quality is also an important determinant of library construction success. Enzymatic inhibitors, such as detergents, carried over during purification of biological samples can lead to reduced final yield, failure of the library prep, or low and uneven coverage when analyzed bioinformatically. Ideally, extraction protocols or systems should be optimized to purify inhibitor-free nucleic acids.

[00127] In this example, DNA was purified from biological samples by two different methods and the isolated DNA was used directly in the construction of library preps for NGS. The quality of the sequencing library preps was directly correlated to the effectiveness of inhibitor removal by the DNA purification methods tested. In one method, saliva was collected from 2 donors into an equal volume of Oragene[®] (DNA Genotek, Ottawa, Canada), a DNA extraction and purification reagent that contains detergent and other sequencing inhibitors, followed by the addition of prepIT[®]-L2P (DNA Genotek), a reagent and method designed to remove inhibitors of downstream analysis, and finally followed by ethanol precipitation to recover purified DNA. In the second method, aliquots of the same saliva

collected into Oragene were simply mixed with the composition of the present invention. Specifically, 100 µl of saliva/Oragene was mixed with 10 µl 2M NH₄Cl and 20 µl of pentanol:Halocarbon Oil 6.3 (1:0.8 (v/v)) and allowed to settle for 20 minutes. The resulting supernatant, containing nucleic acids, was transferred to a clean tube ready for library prep construction (Illumina's Nextera® XT DNA Library Preparation Guide).

[00128] Sequencing libraries were prepared from Oragene/saliva samples treated with the present composition ("STAT") and from purified DNA extracted using Oragene/prepIT·L2P. Prepared libraries were analyzed on an Agilent 2100 Bioanalyzer using the Agilent High Sensitivity DNA Kit. Bioanalyzer gel images (Figure 18a-b) and traces (Figure 19 a-d) show that libraries prepared from saliva samples in which the detergent and other inhibitors have been removed using STAT have the same mean fragment size and fragment length distribution, and a similar concentration as the libraries prepared from purified DNA. Hence, the supernatant of STAT-treated biological samples can be used directly in the construction of library preparations for NGS, saving considerable time and expense.

[00129] All publications, patents and patent applications mentioned in this Specification are indicative of the level of skill of those skilled in the art to which this invention pertains and are herein incorporated by reference to the same extent as if each individual publication, patent, or patent applications was specifically and individually indicated to be incorporated by reference.

[00130] The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.

THE EMBODIMENTS IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A detergent removal system for removing a detergent from an aqueous solution, said system comprising:
 - a. a salt;
 - b. a water immiscible alcohol of Formula I



where R^1 is an optionally substituted, linear, branched or cyclic $C_4 - C_{12}$ alkyl;
and

- c. a water immiscible halocarbon, wherein said halocarbon is miscible with said alcohol of Formula I;

wherein on treatment of the aqueous mixture, a two-phase mixture is formed comprising an aqueous phase and a non-aqueous phase, the non-aqueous phase comprising substantially all of the detergent.
2. The system of claim 1, wherein the detergent is an anionic detergent.
3. The system of claim 1 or 2, wherein the system further removes a detergent-associated and/or detergent-bound molecule from the aqueous solution.
4. The system of claim 3, wherein the detergent-associated and/or detergent-bound molecule is a protein.
5. The system of any one of claims 3 to 4, wherein the detergent and/or the detergent-associated or detergent-bound molecule is an enzymatic inhibitor.
6. The system of any one of claims 1 to 5, wherein the salt is a quaternary ammonium salt or an alkali metal salt.
7. The system of claim 6, wherein the salt is ammonium acetate, ammonium chloride, ammonium sulfate, a betaine salt, choline chloride, diethylamine hydrochloride, dimethylethanolamine, ethanolamine, ethylammonium chloride, methylammonium

chloride, tetra-n-butylammonium acetate, tetraethylammonium chloride monohydrate, tetramethylammonium chloride, tetra-n-propylammonium chloride, methyltri-n-butylammonium chloride, triethylamine hydrochloride, triethylmethylammonium chloride, trimethylamine hydrochloride, an acid salt of 1-butylamine, an acid salt of 1-pentylamine, an acid salt of 1-hexylamine, an acid salt of 1-dodecylamine, lithium chloride; sodium chloride, potassium chloride, or a combination thereof.

8. The system of any one of claims 1 – 7, wherein the water immiscible alcohol is 1-butanol, 3-methyl-1-butanol, 2-butanol, 1-heptanol, 1,2-hexanediol, 1-hexanol, 2-nonanol, 1-pentanol, 4-methyl-2-pentanol, cyclopentanol, 1-undecanol or a combination thereof.
9. The system of claim 7, wherein the salt is ammonium chloride.
10. The system of any one of claims 1 – 9, wherein the halocarbon is 1-bromo-3-chloropropane, 1-bromo-6-chlorohexane, bromodichloromethane (BDCM), chlorodibromomethane, chloroform, 2-iodopropane, poly(chlorotrifluoroethylene), or a combination thereof.
11. The system of any one of claims 1 – 10, wherein the water immiscible alcohol is 1-butanol, 1-pentanol, cyclopentanol, 1-hexanol, 1-heptanol, 2-nonanol or 1-undecanol.
12. The system of claim 11, wherein the water immiscible alcohol is 1-pentanol or cyclopentanol.
13. The system of any one of claims 1 – 12, wherein the halocarbon is BDCM or polychlorotrifluoroethylene.
14. The system of any one of claims 1 – 13, wherein the detergent is sodium dodecyl sulfate (SDS) or Sarkosyl.
15. The system of claim 14 wherein the detergent is SDS.
16. The system of any one of claims 1 to 15, wherein the aqueous solution is a biological sample.

17. The system of claim 16, wherein the biological sample is a modified biological sample comprising a sample storage, lysis or extraction composition.
18. The system of claim 16 or 17, wherein the biological sample comprises saliva, sputum, buccal swab, serum, plasma, blood, pharyngeal, nasal/nasal pharyngeal or sinus swabs or secretions, throat swabs or scrapings, mouthwash sample, urine, mucous, feces, chyme, vomit, gastric juices, pancreatic juices, semen/sperm, cerebral spinal fluid, products of lactation or menstruation, egg yolk, amniotic fluid, aqueous humour, vitreous humour, cervical secretions or swabs, vaginal fluid/secretions/swabs or scrapings, bone marrow aspirates, pleural fluid, sweat, pus, tears, lymph, bronchial, tracheal or lung lavage fluid or aspirates, a cell culture, a cell suspension, connective tissue, epithelium, mucosal membrane, muscle tissue, placental tissue, organ tissue, nerve tissue, hair, skin, nails, plants, plant extracts, algae, microorganisms, a soil sample, sewage, wastewater, foodstuff, or industrial effluent.
19. The system of claim 18, wherein the microorganisms comprise virus, bacteria, yeast, fungi, archaea, and/or protists.
20. The system of claim 1, which comprises ammonium chloride, 1-pentanol and bromodichloromethane or polychlorotrifluoroethylene.
21. The system of claim 1, wherein the salt, the water immiscible alcohol and the water immiscible halocarbon are provided in separate containers.
22. The system of claim 1, wherein the salt, the water immiscible alcohol and the water immiscible halocarbon are provided in a single container.
23. The system of claim 1, wherein the water immiscible alcohol and the water immiscible halocarbon are provided as a single composition in a first container and the salt is provided in a separate, second container.
24. The system of claim 1, which additionally comprises a sample collection container, wherein the sample collection container optionally contains a detergent-containing solution.

25. The system of any one of claims 1 to 24, wherein the non-aqueous phase comprises substantially all of any detergent-associated or detergent-bound protein present, and the aqueous phase is suitable for direct use in a downstream application.
26. The system of claim 25, wherein the downstream application is a polymerase chain reaction (PCR), library preparation, or nucleotide sequencing.
27. The system of claim 26, wherein the PCR is RT-PCR.
28. The system of claim 5, wherein the enzymatic inhibitor is an inhibitor of a downstream application.
29. The system of claim 28, wherein the downstream application is a polymerase chain reaction (PCR), library preparation, or nucleotide sequencing.
30. The system of claim 29, wherein the PCR is RT-PCR.
31. The system of any one of claims 1 to 30, further comprising a reducing agent.
32. The system of claim 31, wherein the reducing agent is dithiothreitol (DTT), mercaptohexanol, mercaptoundecanol, dimercaptopropanol or mercaptobutanol.
33. The system of any one of claims 1 to 32, further comprising a chelator and/or a buffer.
34. The system of claim 33, wherein the chelator is ethylene glycol tetraacetic acid (EGTA), (2-Hydroxyethyl)ethylenediaminetriacetic acid (HEDTA), diethylene triamine pentaacetic acid (DTPA), NitriloTriAcetic Acid (NTA), ethylenediaminetriacetic acid (EDTA), cyclohexanediaminetetraacetic acid (CDTA), citrate anhydrous, sodium citrate, calcium citrate, ammonium citrate, ammonium bicitrate, citric acid, diammonium citrate, ferric ammonium citrate, lithium citrate, or any combination thereof.
35. The system of any one of claims 1 to 34, further comprising a lipophilic stain.
36. The system of claim 35, wherein the lipophilic stain is Nile Red, 9-Anthryldiazomethane, Fluorol Yellow 088, N,N,N-Trimethyl-4-(6-phenyl-1,3,5-hexatrien-1-yl) phenylammonium p-toluenesulfonate (TMA-DPH), 3,3'-

Diocetadecyloxacarbocyanine perchlorate, 1,6-Diphenyl-1,3,5-hexatriene, Sudan III, Sudan Orange G, Nile Blue chloride or Solvent Blue 37.

37. A method of removing a detergent from an aqueous solution comprising said detergent, said method comprising the step of mixing the aqueous solution with:

- a. a salt;
- b. a water immiscible alcohol of Formula I



where R¹ is an optionally substituted, linear, branched or cyclic C₄ - C₁₂ alkyl;
and

- c. a water immiscible halocarbon, wherein said halocarbon is miscible with said alcohol of Formula I,

to form a two-phase mixture, wherein substantially all of the detergent is in a non-aqueous phase.

38. The method of claim 37, wherein the detergent is an anionic detergent.

39. The method of claim 37 or 38, wherein the method further removes a detergent-associated and/or detergent-bound molecule from the aqueous solution.

40. The method of claim 39, wherein the detergent-associated and/or detergent-bound molecule is a protein.

41. The method of claim 39 or 40, wherein the detergent and/or detergent-associated or detergent-bound molecule is an enzymatic inhibitor.


42. The method of any one of claims 37 to 40, wherein the alcohol and the halocarbon are combined prior to mixing with the aqueous solution.

43. The method of any one of claims 37 to 42, additionally comprising the step of separating the aqueous phase from the two-phase mixture.

44. The method of any one of claims 37 to 43, which additionally comprises the step of centrifuging the mixture to facilitate separation of the two phases.
45. The method of any one of claims 37 to 44, wherein the concentration of the salt in the aqueous phase of said two-phase mixture is from about 30mM to about 0.5 M.
46. The method of any one of claims 37 to 45, wherein the halocarbon is present at a concentration sufficient to increase the density of the organic phase to greater than the density of the aqueous phase.
47. The method of claim 46, wherein the concentration of halocarbon in the alcohol is up to about 80% (v/v), for example, about 50% (v/v).
48. The method of any one of claims 37 to 47, wherein the ratio of the total volume of the salt plus the alcohol plus the halocarbon to the volume of the aqueous solution comprising the detergent is from about 1:9 to about 2:1.
49. The method of claim 48, wherein the ratio of the total volume of the salt plus the alcohol plus the halocarbon to the volume of the aqueous solution comprising the detergent is about 1:5.
50. The method of any one of claims 37 to 49, wherein the aqueous solution comprising the detergent is a biological sample.
51. The method of claim 50, wherein the biological sample is a modified biological sample comprising a sample storage, lysis or extraction composition.
52. The method of claim 50 or 51, wherein the biological sample comprises saliva, sputum, buccal swab, serum, plasma, blood, pharyngeal, nasal/nasal pharyngeal or sinus swabs or secretions, throat swabs, urine, mucous, feces, chyme, vomit, gastric juices, pancreatic juices, semen/sperm, cerebral spinal fluid, products of lactation or menstruation, egg yolk, amniotic fluid, aqueous humour, vitreous humour, cervical secretions or swabs, vaginal fluid/secretions/swabs or scrapings, bone marrow aspirates, pleural fluid, sweat, pus, tears, lymph, bronchial or lung lavage, a cell culture, a cell suspension, connective tissue, epithelium, mucosal membrane, muscle tissue, placental tissue, organ tissue, nerve tissue, hair, skin, nails, plants, plant

- extracts, algae, microorganisms, a soil sample, sewage, wastewater, foodstuff, or industrial effluent.
53. The method of claim 52, wherein the microorganisms comprise virus, bacteria, yeast, fungi, archaea, and/or protists.
54. The method of any one of claims 37 to 53, wherein the salt is an ammonium salt or an alkali metal salt.
55. The method of claim 54, wherein the salt is ammonium acetate, ammonium chloride, ammonium sulfate, a betaine salt, choline chloride, diethylamine hydrochloride, dimethylethanolamine, ethanolamine, ethylammonium chloride, methylammonium chloride, tetra-n-butylammonium acetate, tetraethylammonium chloride monohydrate, tetramethylammonium chloride, tetra-n-propylammonium chloride, methyltri-n-butylammonium chloride, triethylamine hydrochloride, triethylmethylammonium chloride, trimethylamine hydrochloride, an acid salt of 1-butylamine, an acid salt of 1-pentylamine, an acid salt of 1-hexylamine, an acid salt of 1-dodecylamine, lithium chloride; sodium chloride, potassium chloride, or a combination thereof.
56. The method of any one of claims 37 to 55, wherein the water immiscible alcohol is 1-butanol, 3-methyl-1-butanol, 2-butanol, 1-heptanol, 1,2-hexanediol, 1-hexanol, 2-nonanol, 1-pentanol, 4-methyl-2-pentanol, cyclopentanol, 1-undecanol or a combination thereof.
57. The method of any one of claims 37 to 56, wherein the halocarbon is 1-bromo-3-chloropropane, 1-bromo-6-chlorohexane, bromodichloromethane (BDCM), chlorodibromomethane, chloroform, 2-iodopropane, polychlorotrifluoroethylene, or a combination thereof.
58. The method of claim 57, wherein the salt is ammonium chloride.
59. The method of any one of claims 37 to 58, wherein the water immiscible alcohol is 1-butanol, 1-pentanol, cyclopentanol, 1-hexanol, 1-heptanol, 2-nonanol or 1-undecanol.
60. The method of claim 59, wherein the water immiscible alcohol is 1-pentanol or cyclopentanol.

61. The method of any one of claims 37 to 60, wherein the halocarbon is BDCM or polychlorotrifluoroethylene.
62. The method of any one of claims 37 to 61, wherein the detergent is sodium dodecyl sulfate (SDS) or Sarkosyl.
63. The method of claim 62, wherein the detergent is SDS.
64. The method of claim 37, wherein the salt is ammonium chloride, the alcohol is 1-pentanol and the halocarbon is bromodichloromethane.
65. The method of claim 37, wherein the salt is ammonium chloride, the alcohol is 1-pentanol, and the halocarbon is polychlorotrifluoroethylene.
66. The method of any one of claims 37 to 65, further comprising the step of directly using a portion of the aqueous phase from the two-phase mixture for a downstream application.
67. The method of claim 66, wherein the downstream application is a polymerase chain reaction (PCR), library preparation, or nucleotide sequencing.
68. The method of claim 67, wherein the PCR is RT-PCR.
69. The method of claim 41, wherein the enzymatic inhibitor is an inhibitor of a downstream application.
70. The method of claim 69, wherein the downstream application is a polymerase chain reaction (PCR), library preparation, or nucleotide sequencing.
71. The method of claim 70, wherein the PCR is RT-PCR.
72. A biphasic composition formed from mixing:
 - a. a salt;
 - b. a water immiscible alcohol of Formula I



I

where R¹ is an optionally substituted, linear, branched or cyclic C₄ - C₁₂ alkyl;
and

- c. a water immiscible halocarbon, wherein said halocarbon is miscible with said alcohol of Formula I; with
- d. an aqueous solution comprising a detergent,

wherein a two-phase mixture is formed comprising an aqueous phase and a non-aqueous phase, such that substantially all of the detergent is in the non-aqueous phase.

73. The biphasic composition of claim 72, wherein the detergent is an anionic detergent.

74. The biphasic composition of 72 or 73, wherein the aqueous solution further comprises a detergent-associated and/or detergent-bound molecule, and wherein in the two-phase mixture, the detergent-associated and/or detergent-bound molecule is in the non-aqueous phase.

75. The biphasic composition of claim 74, wherein the detergent-associated and/or detergent-bound molecule is a protein.

76. The biphasic composition of claim 74 or 75, wherein the detergent and/or detergent-associated or detergent-bound molecule is an enzymatic inhibitor.

77. The biphasic composition of any one of claims 72 to 76, wherein the salt is a quaternary ammonium salt or an alkali metal salt.

78. The biphasic composition of claim 77, wherein the salt is ammonium acetate, ammonium chloride, ammonium sulfate, a betaine salt, choline chloride, diethylamine hydrochloride, dimethylethanolamine, ethanolamine, ethylammonium chloride, methylammonium chloride, tetra-n-butylammonium acetate, tetraethylammonium chloride monohydrate, tetramethylammonium chloride, tetra-n-propylammonium chloride, methyltri-n-butylammonium chloride, triethylamine hydrochloride, triethylmethylammonium chloride, trimethylamine hydrochloride, an acid salt of 1-butylamine, an acid salt of 1-pentylamine, an acid salt of 1-hexylamine, an acid salt of 1-dodecylamine, lithium chloride; sodium chloride, potassium chloride, or a combination thereof.

79. The biphasic composition of any one of claims 72 to 78, wherein the water immiscible alcohol is 1-butanol, 3-methyl-1-butanol, 2-butanol, 1-heptanol, 1,2-hexanediol, 1-hexanol, 2-nonanol, 1-pentanol, 4-methyl-2-pentanol, cyclopentanol, 1-undecanol or a combination thereof.
80. The biphasic composition of any one of claims 72 to 79, wherein the halocarbon is 1-bromo-3-chloropropane, 1-bromo-6-chlorohexane, bromodichloromethane (BDCM), chlorodibromomethane, chloroform, 2-iodopropane, polychlorotrifluoroethylene, or a combination thereof.
81. The biphasic composition of claim 78, wherein the salt is ammonium chloride.
82. The biphasic composition of any one of claims 72 to 81, wherein the water immiscible alcohol is 1-butanol, 1-pentanol, cyclopentanol, 1-hexanol, 1-heptanol, 2-nonanol or 1-undecanol.
83. The biphasic composition of claim 82 wherein the water immiscible alcohol is 1-pentanol or cyclopentanol.
84. The biphasic composition of any one of claims 72 to 83, wherein the halocarbon is BDCM or polychlorotrifluoroethylene.
85. The biphasic composition of any one of claims 72 to 84, wherein the detergent is sodium dodecyl sulfate (SDS) or Sarkosyl.
86. The biphasic composition of claim 85 wherein the detergent is SDS.
87. The biphasic composition of any one of claims 72 to 86, wherein the aqueous solution comprising the detergent is a biological sample.
88. The biphasic composition of claim 87, wherein the biological sample is a modified biological sample comprising a sample storage, lysis or extraction composition.
89. The biphasic composition of claim 87 or 88, wherein the biological sample comprises saliva, sputum, buccal swab, serum, plasma, blood, pharyngeal, nasal/nasal pharyngeal or sinus swabs or secretions, throat swabs, urine, mucous, feces, chyme, vomit, gastric juices, pancreatic juices, semen/sperm, cerebral spinal fluid, products of

lactation or menstruation, egg yolk, amniotic fluid, aqueous humour, vitreous humour, cervical secretions or swabs, vaginal fluid/secretions/swabs or scrapings, bone marrow aspirates, pleural fluid, sweat, pus, tears, lymph, bronchial or lung lavage, a cell culture, a cell suspension, connective tissue, epithelium, mucosal membrane, muscle tissue, placental tissue, organ tissue, nerve tissue, hair, skin, nails, plants, plant extracts, algae, microorganisms, a soil sample, sewage, wastewater, foodstuff, or industrial effluent.

90. The biphasic composition of claim 89, wherein the microorganisms comprise virus, bacteria, yeast, fungi, archaea, and/or protists.
91. The biphasic composition of claim 72, which comprises ammonium chloride, 1-pentanol and bromodichloromethane.
92. The biphasic composition of claim 72, which comprises ammonium chloride, 1-pentanol, and polychlorotrifluoroethylene.
93. The biphasic composition of any one of claims 72 to 92, wherein the aqueous phase is suitable for direct use in a downstream application.
94. The biphasic composition of claim 93, wherein the downstream application is a polymerase chain reaction (PCR), library preparation, or nucleotide sequencing.
95. The biphasic composition of claim 94, wherein the PCR is RT-PCR.
96. The biphasic composition of claim 76, wherein the enzymatic inhibitor is an inhibitor of a downstream application.
97. The biphasic composition of claim 96, wherein the downstream application is a polymerase chain reaction (PCR), library preparation, or nucleotide sequencing.
98. The biphasic composition of claim 97, wherein the PCR is RT-PCR.
99. The biphasic composition of any one of claims 72 to 98, further comprising a reducing agent.

100. The biphasic composition of claim 99, wherein the reducing agent is dithiothreitol (DTT), mercaptohexanol, mercaptoundecanol, dimercaptopropanol or mercaptobutanol.
101. The biphasic composition of any one of claims 72 to 100, further comprising a chelator and/or a buffer.
102. The biphasic composition of claim 101, wherein the chelator is ethylene glycol tetraacetic acid (EGTA), (2-Hydroxyethyl)ethylenediaminetriacetic acid (HEDTA), diethylene triamine pentaacetic acid (DTPA), NitriTriAcetic Acid (NTA), ethylenediaminetriacetic acid (EDTA), cyclohexanediaminetetraacetic acid (CDTA), citrate anhydrous, sodium citrate, calcium citrate, ammonium citrate, ammonium bicitrate, citric acid, diammonium citrate, ferric ammonium citrate, lithium citrate, or any combination thereof.
103. The biphasic composition of any one of claims 72 to 102, further comprising a lipophilic stain.
104. The biphasic composition of claim 103, wherein the lipophilic stain is Nile Red, 9-Anthryldiazomethane, Fluorol Yellow 088, N,N,N-Trimethyl-4-(6-phenyl-1,3,5-hexatrien-1-yl) phenylammonium p-toluenesulfonate (TMA-DPH), 3,3'-Diocadecyloxacarbocyanine perchlorate, 1,6-Diphenyl-1,3,5-hexatriene, Sudan III, Sudan Orange G, Nile Blue chloride or Solvent Blue 37.
105. A kit for removal of a detergent from an aqueous solution comprising said detergent, said kit comprising:
- a salt;
 - a water immiscible alcohol of Formula I



where R¹ is an optionally substituted, linear, branched or cyclic C₄ - C₁₂ alkyl;

- a water immiscible halocarbon, wherein said halocarbon is miscible with said alcohol of Formula I;

- d. at least one reagent container; and, optionally
- e. instruction(s) for use.

106. The kit of claim 105, wherein the detergent is an anionic detergent.
107. The kit of claim 105 or 106, wherein the kit is further for the removal of a detergent-associated and/or detergent-bound molecule from the aqueous solution.
108. The kit of claim 107, wherein the detergent-associated or detergent-bound molecule is a protein.
109. The kit of any one of claims 107 to 108, wherein the detergent and/or detergent-associated or detergent-bound molecule is an enzymatic inhibitor.
110. The kit of any one of claims 105 to 109, wherein the salt is a quaternary ammonium salt or an alkali metal salt.
111. The kit of claim 110, wherein the salt is ammonium acetate, ammonium chloride, ammonium sulfate, a betaine salt, choline chloride, diethylamine hydrochloride, dimethylethanolamine, ethanolamine, ethylammonium chloride, methylammonium chloride, tetra-n-butylammonium acetate, tetraethylammonium chloride monohydrate, tetramethylammonium chloride, tetra-n-propylammonium chloride, methyltri-n-butylammonium chloride, triethylamine hydrochloride, triethylmethylammonium chloride, trimethylamine hydrochloride, an acid salt of 1-butylamine, an acid salt of 1-pentylamine, an acid salt of 1-hexylamine, an acid salt of 1-dodecylamine, lithium chloride; sodium chloride, potassium chloride, or a combination thereof.
112. The kit of any one of claims 105 to 111, wherein the water immiscible alcohol is 1-butanol, 3-methyl-1-butanol, 2-butanol, 1-heptanol, 1, 2-hexanediol, 1-hexanol, 2-nonanol, 1-pentanol, 4-methyl-2-pentanol, cyclopentanol, 1-undecanol or a combination thereof.
113. The kit of any one of claims 105 to 112, wherein the halocarbon is 1-bromo-3-chloropropane, 1-bromo-6-chlorohexane, bromodichloromethane (BDCM), chlorodibromomethane, chloroform, 2-iodopropane, polychlorotrifluoroethylene, or a combination thereof.

114. The kit of claim 111, wherein the salt is ammonium chloride.
115. The kit of any one of claims 105 to 114, wherein the water immiscible alcohol is 1-butanol, 1-pentanol, cyclopentanol, 1-hexanol, 1-heptanol, 2-nonanol or 1-undecanol.
116. The kit of claim 115 wherein the water immiscible alcohol is 1-pentanol or cyclopentanol.
117. The kit of any one of claims 105 to 116, wherein the halocarbon is BDCM or polychlorotrifluoroethylene.
118. The kit of any one of claims 105 to 117, wherein the detergent is sodium dodecyl sulfate (SDS) or Sarkosyl.
119. The kit of claim 118, wherein the detergent is SDS.
120. The kit of any one of claims 105 to 119, wherein the aqueous solution comprising the detergent is a biological sample.
121. The kit of claim 120, wherein the biological sample is a modified biological sample comprising a sample storage, lysis or extraction composition.
122. The kit of claim 120 or 121, wherein the biological sample comprises saliva, sputum, buccal swab, serum, plasma, blood, pharyngeal, nasal/nasal pharyngeal or sinus swabs or secretions, throat swabs, urine, mucous, feces, chyme, vomit, gastric juices, pancreatic juices, semen/sperm, cerebral spinal fluid, products of lactation or menstruation, egg yolk, amniotic fluid, aqueous humour, vitreous humour, cervical secretions or swabs, vaginal fluid/secretions/swabs or scrapings, bone marrow aspirates, pleural fluid, sweat, pus, tears, lymph, bronchial or lung lavage, a cell culture, a cell suspension, connective tissue, epithelium, mucosal membrane, muscle tissue, placental tissue, organ tissue, nerve tissue, hair, skin, nails, plants, plant extracts, algae, microorganisms, a soil sample, sewage, wastewater, foodstuff, or industrial effluent.
123. The kit of claim 122, wherein the microorganisms comprise virus, bacteria, yeast, fungi, archaea, and/or protists.

124. The kit of claim 105, which comprises ammonium chloride, 1-pentanol and bromodichloromethane.
125. The kit of claim 105, which comprises ammonium chloride, 1-pentanol, and polychlorotrifluoroethylene.
126. The kit of any one of claims 105 to 125, which additionally comprises a sample collection container.
127. The kit of any one of claims 105 to 126, for direct use in a downstream application.
128. The kit of claim 127, wherein the downstream application is polymerase chain reaction (PCR), library preparation, or nucleotide sequencing.
129. The kit of claim 128, wherein the PCR is RT-PCR.
130. The kit of claim 109, wherein the enzymatic inhibitor is an inhibitor of a downstream application.
131. The kit of claim 130, wherein the downstream application is a polymerase chain reaction (PCR), library preparation, or nucleotide sequencing.
132. The kit of claim 131, wherein the PCR is RT-PCR.
133. The kit of any one of claims 105 to 132, further comprising a reducing agent.
134. The kit of claim 133, wherein the reducing agent is dithiothreitol (DTT), mercaptohexanol, mercaptoundecanol, dimercaptopropanol or mercaptobutanol.
135. The kit of any one of claims 105 to 134, further comprising a chelator and/or a buffer.
136. The kit of claim 135, wherein the chelator is ethylene glycol tetraacetic acid (EGTA), (2-Hydroxyethyl)ethylenediaminetriacetic acid (HEDTA), diethylene triamine pentaacetic acid (DTPA), NitrioloTriAcetic Acid (NTA), ethylenediaminetriacetic acid (EDTA), cyclohexanediaminetetraacetic acid (CDTA), citrate anhydrous, sodium citrate, calcium citrate, ammonium citrate, ammonium bicitrate, citric acid, diammonium citrate, ferric ammonium citrate, lithium citrate, or any combination thereof.

137. The kit of any one of claims 105 to 136, further comprising a lipophilic stain.

138. The kit of claim 137, wherein the lipophilic stain is Nile Red, 9-Anthryldiazomethane, Fluorol Yellow 088, N,N,N-Trimethyl-4-(6-phenyl-1,3,5-hexatrien-1-yl) phenylammonium p-toluenesulfonate (TMA-DPH), 3,3'-Dioctadecyloxycarbocyanine perchlorate, 1,6-Diphenyl-1,3,5-hexatriene, Sudan III, Sudan Orange G, Nile Blue chloride or Solvent Blue 37.

2026201397 25 Feb 2026




FIGURE 1




FIGURE 2




FIGURE 3

2026201397 25 Feb 2026




FIGURE 4




FIGURE 5

2026201397 25 Feb 2026




FIGURE 6




FIGURE 7

2026201397 25 Feb 2026




FIGURE 8

2026201397 25 Feb 2026

Marker 1kb+ Sample




FIGURE 9




FIGURE 10

2026201397 25 Feb 2026




FIGURE 11

2026201397 25 Feb 2026




FIGURE 12




FIGURE 13

2026201397 25 Feb 2026




FIGURE 14

25 Feb 2026

2026201397




FIGURE 15

25 Feb 2026

2026201397

1 2 3 4 5 6 7 8 9 10 11 12



FIGURE 16

2026201397 25 Feb 2026




FIGURE 17

2026201397 25 Feb 2026




FIGURE 18A

2026201397 25 Feb 2026




FIGURE 18B

2026201397 25 Feb 2026




FIGURE 19A




FIGURE 19B

2026201397 25 Feb 2026




FIGURE 19C




FIGURE 19D